Ardelyx (ARDX) Following Strong Results And Guidance Still Looks Undervalued

Ardelyx (ARDX) stock is in focus after the company reported second quarter 2026 results on 6 August, showing higher revenue, narrower net losses, and updated full year guidance for IBSRELA and XPHOZAH.

See our latest analysis for Ardelyx.

Ardelyx’s recent earnings update came after a tough stretch for the stock, with the share price down 24.62% over the past month and 36.26% year to date, even though the 5 year total shareholder return of 166.67% still reflects a much stronger longer term outcome.

If you are reassessing your watchlist after Ardelyx’s recent move, this can be a good moment to broaden your search and uncover 42 healthcare AI stocks

After the earnings bump in revenue and guidance, yet a sharp slide in Ardelyx’s share price, the real question now is whether the current valuation still tilts the risk reward in favour of new buyers or patient holders.

Most Popular Narrative: 76% Undervalued

Ardelyx closed at $3.92, while the most followed narrative places fair value at $16.33. That wide gap frames how investors may view the latest sell off.

The rising prevalence of chronic kidney disease (CKD) and gastrointestinal disorders driven by an aging population continues to expand Ardelyx's core addressable markets, supporting sustained long-term demand for IBSRELA and XPHOZAH and driving future revenue growth. Recent and ongoing improvements in market access, prescription pull-through, and expansion of the sales force are boosting prescriber breadth and depth, contributing to accelerating product adoption and positioning the company to achieve strong topline growth and improved gross margins as fixed costs are leveraged.

Read the complete narrative.

Want to see what sits behind that growth story? The narrative leans heavily on aggressive revenue expansion, rising margins and a richer earnings multiple to justify that fair value.

Result: Fair Value of $16.33 (UNDERVALUED)

Have a read of the narrative in full and understand what's behind the forecasts.

However, Ardelyx still faces meaningful risks, including its heavy dependence on IBSRELA and XPHOZAH, as well as uncertainty around reimbursement outcomes that could undercut the bullish earnings narrative.

Find out about the key risks to this Ardelyx narrative.

Next Steps

This mix of optimism and concern around Ardelyx can feel conflicting, so consider the details carefully and weigh the trade off yourself with 4 key rewards and 1 important warning sign

Looking for more ideas beyond Ardelyx?

If Ardelyx is already on your radar, do not stop there. The Simply Wall Street Screener can surface fresh opportunities you might otherwise miss.

• Spot potential income anchors for your portfolio by reviewing companies we highlight as 11 dividend fortresses
• Hunt for value opportunities that combine quality and attractive pricing through our focused set of 50 high quality undervalued stocks
• Prioritise resilience by scanning companies identified as 79 resilient stocks with low risk scores

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com